Edgewise Therapeutics, Inc.
EWTX
株式のランク
#3981
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
株価
$39.17
時価総額
$4.21B
変化（1日）
3.28%
変化（1年）
154.48%
国
US
取引 Edgewise Therapeutics, Inc. (EWTX)
カテゴリー
Healthcare
Edgewise Therapeutics, Inc.（EWTX）のP/B比率
October 2026 時点のP/B比率 TTM: 8.90
Edgewise Therapeutics, Inc. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 8.90 です。2023 年末時点でのP/B比率は 2.19 でした。
Edgewise Therapeutics, Inc. の P/B 比率の履歴（2019 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 8.90 | 65.65% |
| 2024 | 5.37 | 145.74% |
| 2023 | 2.19 | 58.22% |
| 2022 | 1.38 | -49.87% |
| 2021 | 2.76 | -106.24% |
| 2020 | -44.18 | -49.57% |
| 2019 | -87.61 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| 6.251 | -29.73% |
US
|
|
| 13.2547 | 49.00% |
US
|
|
| 4.208 | -52.70% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -30.50% |
NL
|
